Oncocyte Corp has provided financial information for the year ended December 31, 2022, and discussed their products, including VitaGraft, DetermaIO, DetermaCNI, and DetermaRx, as well as their plans for development and commercialization. They also mentioned a Nasdaq listing, a workforce reduction plan, and a stock purchase agreement with Dragon Scientific, LLC for the sale of 70% of the equity interests of Razor Genomics Inc. The company reported a net loss of $72.9 million for the year. They identified material weaknesses in their internal control over financial reporting and stated that their financial statements are not yet final. Forward-looking statements were also included in the filing.